首页> 外文OA文献 >Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis

【2h】

Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis

机译：双特异性T细胞参与者（咬合）抗体Blinatumab用于治疗复发/难治急性淋巴细胞白血病和非霍奇金淋巴瘤的疗效和安全性：系统性评论和荟萃分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Jian Yu; Wen Wang; He Huang;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis [J] . Yu Jian, Wang Wen, Huang He Hematology. . 2019,第1期

机译：双特异性T细胞参录（咬合）抗体Blinatumab用于治疗复发/难治性急性淋巴细胞白血病和非霍奇金淋巴瘤的疗效和安全性：全身评测和荟萃分析
2. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis [J] . Jian Yu, Wen Wang, He Huang Hematology . 2019,第1期

机译：双特异性T细胞参与者（咬合）抗体Blinatumab用于治疗复发/难治急性淋巴细胞白血病和非霍奇金淋巴瘤的疗效和安全性：系统性评论和荟萃分析
3. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study [J] . Goebeler Maria-Elisabeth, Knop Stefan, Viardot Andreas, Journal of Clinical Oncology . 2016,第10期

机译：双特异性T细胞Engager（BiTE）抗体构建物Blinatumomab用于治疗复发/难治性非霍奇金淋巴瘤的患者：I期研究的最终结果
4. Design and Characterization of Bispecific Chemically Self-Assembled Antibody Nanoring(CSAN) T-Cell Engagers That Target CD22+ B- Leukemias or Lymphomas [C] . Jingjing Shen, Adrian Fegan, Daniel A. Vallera, PEGS . 2015

机译：靶向CD22 + B-白血病或淋巴瘤的双特化学自组装抗体纳米（CSAN）T细胞啮合的设计与表征
5. Comparative pharmacology of the human CD19/CD3 Bispecific T-cell engager (BiTERTM) antibody blinatumomab with the hybrid murine surrogate CD19/CD3 BiTE antibody hyS103. [D] . Fuhrmann, Stacy R. 2010

机译：人CD19 / CD3双特异性T细胞衔接子（BiTERTM）抗体blinatumomab与杂种鼠替代CD19 / CD3 BiTE抗体hyS103的比较药理学。
6. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma [O] . Andreas Viardot, Marie-Elisabeth Goebeler, Georg Hess, -1

机译：双特异性T细胞接合剂（BiTE）抗体blinatumomab在复发/难治性弥漫性大B细胞淋巴瘤中的2期研究
7. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia [O] . 2015

机译：Blinatumomab：抗CD19 / CD3的双特异性T细胞接合剂（BiTE）抗体，用于难治性急性淋巴白血病

Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis

著录项

引文网络

相似文献

相关主题

期刊订阅